B+
Bull case
20%
Probability
Target price
$2.88
-96.9% vs current
INBX
Inhibrx BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$1.92
-97.9% vs current
B-
Bear case
30%
Probability
Target price
$1.15
-98.8% vs current
AI sentiment snapshot
Latest data as of 2025-11-17
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Investor sentiment is cautious: trading reflects binary clinical risk and funding uncertainty, with limited conviction until clear readouts or confirmed partnership milestones [#10Qp12]. Some optimism exists around potential collaborations, but overall positioning remains defensive pending catalyst delivery [#PR-2025-09-12].
RankAlpha Sentiment AI - 2025-11-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-03-31eventClinical readouts for lead programsHigh impact
Upcoming/ongoing trial readouts for lead candidates that can produce binary moves; positive efficacy or clean safety data should re-rate the stock, while negative signals would drive steep downside [#10Qp12].
2026-06-30catalystCash runway / financing updateHigh impact
Near‑term cash burn and financing needs are a key risk; announcements of dilution or weak funding options would compress valuation significantly.
2026-09-30catalystPartnership or licensing executionHigh impact
A strategic collaboration or favorable licensing terms would de‑risk development and extend runway; execution and milestone delivery determine magnitude of upside.
Recommendation
N/A
No formal recommendation provided.
As of 2025-11-17 • Updated nightlySource: Internal modelMethodology